Leonteq Securities AG’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-3,202
Closed -$501K 1451
2025
Q3
$501K Buy
3,202
+1,275
+66% +$202K 0.02% 411
2025
Q2
$292K Sell
1,927
-222
-10% -$29.6K 0.01% 482
2025
Q1
$323K Buy
2,149
+1,665
+344% +$279K 0.02% 452
2024
Q4
$89.3K Buy
+484
New +$93.2K 0.01% 715
2024
Q1
Sell
-64
Closed -$15.1K 1220
2023
Q4
$15.1K Sell
64
-448
-88% -$88.1K ﹤0.01% 959
2023
Q3
$100K Buy
512
+508
+12,700% +$104K 0.01% 650
2023
Q2
$841 Sell
4
-126
-97% -$25.1K ﹤0.01% 1178
2023
Q1
$26.2K Hold
130
﹤0.01% 905
2022
Q4
$28.3K Sell
130
-987
-88% -$216K ﹤0.01% 926
2022
Q3
$220K Hold
1,117
0.01% 510
2022
Q2
$239K Hold
1,117
0.01% 517
2022
Q1
$317K Sell
1,117
-937
-46% -$289K 0.01% 502
2021
Q4
$774K Sell
2,054
-110
-5% -$42.7K 0.03% 377
2021
Q3
$893K Buy
2,164
+1,664
+333% +$691K 0.04% 321
2021
Q2
$185K Hold
500
0.01% 589
2021
Q1
$145K Hold
500
0.01% 602
2020
Q4
$125K Buy
+500
New +$119K 0.01% 645

Other funds holding CRL

Leonteq Securities AG's CRL Position: Q4 2025 in Review

Leonteq Securities AG sold out of Charles River Laboratories (CRL) in Q4 2025, closing a stake of 3,202 shares — an estimated $501K sold.

Leonteq Securities AG first reported a position in CRL in Q4 2020 and held it in 17 quarters. The position peaked at $893K in Q3 2021. 582 funds tracked by Wall St. Rank hold CRL as of Q4 2025.

  • Leonteq Securities AG reported no remaining Charles River Laboratories position as of Q4 2025 after selling out during the quarter.
  • Leonteq Securities AG sold 3,202 Charles River Laboratories shares in Q4 2025, an estimated $501K.
  • Leonteq Securities AG first reported a position in Charles River Laboratories in Q4 2020 and held it in 17 quarters.
  • Leonteq Securities AG's Charles River Laboratories position peaked at $893K in Q3 2021.
  • 582 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.

Based on Leonteq Securities AG's 13F filing for Q4 2025, filed 6 Feb 2026.